We are pleased to announce that our invested company – New Horizon Health (6606.HK, “NHH”) has completed its Hong Kong Main Board IPO on 18th February 2021. Its public offering over-subscribed for over 4,000 times.

The IPO price of the Company was set at HKD 26.66 per share and has made a remarkable opening price on 18 February at HKD 76.0 per share with a 185.1% increment.

New Horizon Health is a leading Chinese molecular diagnostic company focusing on early cancer detection.

VMS led the Series C round financing of NHH in 2019 and participated in its Series D round financing in 2020.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.